By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Biotechnology. According to news reporting out of Vadodara, India, by NewsRx editors, research stated, "The epidermal growth factor receptor (EGFR) is a cell-surface receptor belonging to ErbB family of tyrosine kinase and it plays a vital role in the regulation of cell proliferation, survival and differentiation. However; EGFR is aberrantly activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with development of variety of tumors."
Our news journalists obtained a quote from the research from the Maharaja Sayajirao University of Baroda, "Therefore, specific EGFR inhibition is one of the key targets for cancer therapy. Two major approaches have been developed and demonstrated benefits in clinical trials for targeting EGFR; monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKIs). EGFR inhibitors like, cetuximab, panitumumab, etc. (mAbs) and gefitinib, erlotinib, lapatinib, etc. (TKIs) are now commercially available for treatment of variety of cancers. Recently, many other agents like peptides, nanobodies, affibodies and antisense oligonucleotide have also shown better efficacy in targeting and inhibiting EGFR. Now a days, efforts are being focused to identify molecular markers that can predict patients more likely to respond to anti-EGFR therapy; to find out combinatorial approaches with EGFR inhibitors and to bring new therapeutic agents with clinical efficacy."
According to the news editors, the research concluded: "In this review we have outlined the role of EGFR in cancer, different types of EGFR inhibitors, preclinical and clinical status of EGFR inhibitors as well as summarized the recent efforts made in the field of molecular EGFR targeting."
For more information on this research see: Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013;34(34):8690-8707. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
Our news journalists report that additional information may be obtained by contacting C. Yewale, Maharaja Sayajirao University of Baroda, Dept. of Pharm, Fac Engn & Technol, Vadodara 390001, Gujarat, India. Additional authors for this research include D. Baradia, I. Vhora, S. Patil and A. Misra (see also technology.html">Biotechnology).
Keywords for this news article include: Asia, Biotechnology, India, Vadodara, Genetics, Oncology, Protein Kinases, Membrane Proteins, Peptide Receptors, Pre-Trial Research, Cancer Gene Therapy, Phosphotransferases, Clinical Trials and Studies, Epidermal Growth Factor Receptor, Receptor Protein-Tyrosine Kinases, Gastrointestinal Hormone Receptors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC